Application | Comment | Organism |
---|---|---|
pharmacology | ADI has anti-cancer activity by causing depletion of L-arginine, fusion of ADI to 20 kDa PEG improves its pharmaceutical efficiency by increasing the half-life of the enzyme in serum, clinical studies, overview | Mycoplasma hominis |
Cloned (Comment) | Organism |
---|---|
expression in Escherichia coli | Mycoplasma hominis |
Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|
46000 | - |
x * 46000, about, SDS-PAGE | Mycoplasma hominis |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
L-arginine + H2O | Mycoplasma hominis | - |
L-citrulline + NH3 | - |
? | |
additional information | Mycoplasma hominis | ADI has anti-cancer activity by causing depletion of L-arginine by reducing the circulating amount, fusion of ADI to 20 kDa PEG improves its pharmaceutical efficiency, overview | ? | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mycoplasma hominis | - |
- |
- |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
L-arginine + H2O | - |
Mycoplasma hominis | L-citrulline + NH3 | - |
? | |
additional information | ADI has anti-cancer activity by causing depletion of L-arginine by reducing the circulating amount, fusion of ADI to 20 kDa PEG improves its pharmaceutical efficiency, overview | Mycoplasma hominis | ? | - |
? |
Subunits | Comment | Organism |
---|---|---|
? | x * 46000, about, SDS-PAGE | Mycoplasma hominis |
Synonyms | Comment | Organism |
---|---|---|
ADI | - |
Mycoplasma hominis |